Skip to content

KORU Medical Systems KRMD Federal Research Credit Carryforward

Federal Research Credit Carryforward at other companies

Opus Genetics logo
Opus GeneticsIRD
$0
Hippo Holdings logo
Hippo HoldingsHIPO
$11.9M+14.4%
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$850K+49.9%
VirnetX Holding Corp
 logo
VirnetX Holding Corp VHC
$1.54M+38.5%
CVD Equipment Corp. logo
CVD Equipment Corp.CVV
$1.72M+0.1%
Motorcar Parts of America logo
Motorcar Parts of AmericaMPAA
$114K-90.1%

Other financials

Income statement

See full
Revenue$11.8M+22.1%
Gross profit$7.2M+19.6%
Operating income-$864.9K+30.5%
Net income-$807.1K+30.8%
EPS (diluted)-$0.02+33.3%

Balance sheet

See full
Cash & equivalents$8.8M+0.4%
Total debt$3.5M-2.8%
Total equity$16.9M+3.5%
Total assets$28.6M+5.1%

Cash flow

See full
Operating cash flow$14.7K+106%
CapEx$46.2K-89.6%
Free cash flow-$31.5K+95.4%

Valuation

See full
Market cap$206.24M+24.9%
Enterprise value$200.96M+25.1%
P/S4.8×+0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin-6%-2.3pp
Net margin-5.3%-2.1pp
FCF margin-37.1%+23.7pp

Returns & leverage

See full
Return on equity-13.7%-4.8pp
Debt / equity0.2×0.0×
Current ratio2.3×-0.1×

Where this comes from

Reported directly by KORU Medical Systems in its filing.

Tagged under the XBRL concept krmd:FederalResearchCreditCarryforward.

The official record: KORU Medical Systems’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KORU Medical Systems's federal research credit carryforward.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KORU Medical Systems's federal research credit carryforward?
KORU Medical Systems (KRMD) reported federal research credit carryforward of $113.2K in Q4 2025.
What does federal research credit carryforward mean?
This reflects the balance of unused federal tax credits generated from qualified research and development expenditures that can be carried forward to offset future federal income tax obligations. It indicates the company's historical commitment to innovation and product development, such as the engineering of medical infusion systems. This asset provides a mechanism to lower the effective tax rate in future profitable periods.